Arisglobal's Lifesphere Safety Bolsters Market Leading Position In Pharmacovigilance

Fremont, CA: The life sciences industry has always been driven by research and innovation, and more so now than ever, with breakthroughs in drug development, investments in accelerating drug launches, and opportunities in medical advancement.

ArisGlobal, the leading provider of life sciences software that automates core drug development functions with its end-to-end technology platform LifeSphere, has shown significant growth in the global adoption of its LifeSphere Safety platform bolstering its position as the most used drug safety software across the world. LifeSphere Safety, an innovative safety suite that has been in development for 30 years, processes the largest number of safety cases across a customer base that includes emerging biotechs, top 5 pharmaceutical companies, and key regulatory entities such as the FDA.

LifeSphere, which provides safety case management efficiency gains of up to 80 percent, is the preferred pharmacovigilance technology for 4 of the 5 largest biopharmas, with the largest global biopharma recently choosing LifeSphere Safety in late 2021.

"With the current and future steep rise of adverse events, pharmacovigilance has become an increasingly strategic area for life sciences organizations. Leveraging automation technology with a scalable architecture is a growing necessity for organizations to bring safer drugs to market, faster," stated Steve Nuckols, Chief Revenue Officer at ArisGlobal. "For many years, LifeSphere Safety has been on a growing adoption trajectory in the industry, including the world's top pharmaceutical companies. We're continuing with our momentum and investing more resources to accelerate our growth."